Literature DB >> 10862799

Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.

C Menaa1, S V Reddy, N Kurihara, H Maeda, D Anderson, T Cundy, J Cornish, F R Singer, J M Bruder, G D Roodman.   

Abstract

Paget's disease is characterized by highly localized areas of increased osteoclast (OCL) activity. This suggests that the microenvironment in pagetic lesions is highly osteoclastogenic, or that OCL precursors in these lesions are hyperresponsive to osteoclastogenic factors (or both). To examine these possibilities, we compared RANK ligand (RANKL) mRNA expression in a marrow stromal cell line developed from a pagetic lesion (PSV10) with that in a normal stromal cell line (Saka), and expression in marrow samples from affected bones of Paget's patients with that in normal marrow. RANKL mRNA was increased in PSV10 cells and pagetic marrow compared with Saka cells and normal marrow, and was also increased in marrow from affected bones compared with uninvolved bones from Paget's patients. Furthermore, pagetic marrow cells formed OCLs at much lower RANKL concentrations than did normal marrow. Anti-IL-6 decreased the RANKL responsivity of pagetic marrow to normal levels, whereas addition of IL-6 to normal marrow enhanced RANKL responsivity. Thus, RANKL expression and responsivity is increased in pagetic lesions, in part mediated by IL-6. These data suggest that the combination of enhanced expression of RANKL in affected bones and increased RANKL sensitivity of pagetic OCL precursors may contribute to the elevated numbers of OCLs in Paget's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862799      PMCID: PMC378510          DOI: 10.1172/JCI9133

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Osteoclast ultrastructure in Paget's disease.

Authors:  A Rebel; K Malkani; M Baslé; C Bregeon
Journal:  Calcif Tissue Res       Date:  1976-04-20

2.  TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

Authors:  B R Wong; J Rho; J Arron; E Robinson; J Orlinick; M Chao; S Kalachikov; E Cayani; F S Bartlett; W N Frankel; S Y Lee; Y Choi
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

3.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

Authors:  G D Roodman; N Kurihara; Y Ohsaki; A Kukita; D Hosking; A Demulder; J F Smith; F R Singer
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures.

Authors:  N Kurihara; C Chenu; M Miller; C Civin; G D Roodman
Journal:  Endocrinology       Date:  1990-05       Impact factor: 4.736

Review 5.  Paget's disease of bone.

Authors:  A J Yates
Journal:  Baillieres Clin Endocrinol Metab       Date:  1988-02

6.  Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease.

Authors:  A Kukita; C Chenu; L M McManus; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.

Authors:  L C Hofbauer; D L Lacey; C R Dunstan; T C Spelsberg; B L Riggs; S Khosla
Journal:  Bone       Date:  1999-09       Impact factor: 4.398

8.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.

Authors:  N Kurihara; D Bertolini; T Suda; Y Akiyama; G D Roodman
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

9.  Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease.

Authors:  J A Hoyland; A J Freemont; P T Sharpe
Journal:  J Bone Miner Res       Date:  1994-01       Impact factor: 6.741

10.  Development and characterization of a human marrow stromal cell line that enhances osteoclast-like cell formation.

Authors:  S Takahashi; S V Reddy; M Dallas; R Devlin; J Y Chou; G D Roodman
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

View more
  28 in total

1.  Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Kei Yamana; Laëtitia Michou; Côme Rousseau; Jean Morissette; Deborah L Galson; Jumpei Teramachi; Hua Zhou; David W Dempster; Jolene J Windle; Jacques P Brown; G David Roodman
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 2.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 3.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

4.  Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.

Authors:  Srinivasan Shanmugarajan; Rimon F Youssef; Parmita Pati; William L Ries; D Sudhaker Rao; Sakamuri V Reddy
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

5.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

6.  Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo.

Authors:  Kazuaki Miyagawa; Yasuhisa Ohata; Jesus Delgado-Calle; Jumpei Teramachi; Hua Zhou; David D Dempster; Mark A Subler; Jolene J Windle; John M Chirgwin; G David Roodman; Noriyoshi Kurihara
Journal:  JCI Insight       Date:  2020-03-26

7.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

8.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.

Authors:  Yuko Hiruma; Tadashi Honjo; Diane F Jelinek; Jolene J Windle; Jaekyoon Shin; G David Roodman; Noriyoshi Kurihara
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

9.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

10.  Gene expression profile in osteoclasts from patients with Paget's disease of bone.

Authors:  Laetitia Michou; Estelle Chamoux; Julie Couture; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.